Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center

BACKGROUND: Neutralizing antibodies cocktail (casirivimab and imdevimab) has received emergency use authorization recommendation by Food and Drug Administration (FDA) and WHO for mild-to-moderate COVID-19 infection in specific high-risk groups. Antibodies cocktail has shown promising results in prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwah, Vikas, Choudhary, Robin, Adhikari, Sudipt, Pemmaraju, Arpita, Menon, A.S., Manrai, Manish, Ajai Kumar, Tentu, Verma, Shipra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193195/
https://www.ncbi.nlm.nih.gov/pubmed/37360888
http://dx.doi.org/10.1016/j.mjafi.2023.03.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193195/
https://www.ncbi.nlm.nih.gov/pubmed/37360888
http://dx.doi.org/10.1016/j.mjafi.2023.03.006

Ejemplares similares